tbuckley/cabot-search huggingface dataset:
PTH-147 Weight loss in patients undergoing oesophagectomy/total gastrectomy (TG) for oesophagogastric (OG) cancer
Authors: O Hynes, A Champion, A Gardiner, A Davies, J Gossage
Journal: Gut (2015)

<h3>Introduction</h3> Weight loss is a predictor of poorer outcomes in patients undergoing OG cancer surgery. Patients present with weight loss and difficulties with eating and drinking. The majority will receive neoadjuvant chemotherapy (NAC) which may further impact on nutritional status. This study looks at the effect of weight loss on postoperative hospital length of stay (LOS) in patients undergoing Oesophagectomy/TG for OG cancer. <h3>Method</h3> A retrospective observational study was carried out on 74 patients who underwent Oesophagectomy/TG for OG cancer at GSTFT in 2014. Data on preoperative weight loss, NAC and postoperative LOS was collated. Weight loss was assessed by comparing weight at diagnosis to weight on the day before surgery. For patients who were weight stable/gain, further assessment of weight loss during NAC was undertaken. <h3>Results</h3> Two patients died in hospital and were excluded. Two patients did not have any information available of preoperative weight changes and so were also excluded. Table 1apresents the demographics and descriptive statistics (using Microsoft Xcel) of results for the total study population (<i>n = 7</i>). Table 1bdisplays the demographics and descriptive statistics for the subgroup of patients who were weight stable/gain overall preoperatively. Patients who are weight stable throughout chemotherapy have a shorter median LOS than those who lose weight and regain it. <h3>Conclusion</h3> Patients who lose weight before surgery are likely to stay in hospital for longer afterwards. The results of this study support the need for preoperative nutritional optimisation in this patient population. The subgroup analysis, although a small sample size, supports a proactive rather than reactive approach to this. In many centres, Dietitian referral relies on the presence of weight loss or nutritional problems. Further studies are required to elucidate optimal preoperative nutritional interventions to improve treatment and patient reported outcomes. <h3>Disclosure of interest</h3> None Declared.
Donald Drummond Webster
Authors: John Walton, Lord Walton of Detchant
Journal: BMJ (2008)

Donald Webster and I were allocated the same lodgings when we entered Newcastle Medical School in 1941, and he became a very close friend. When we each married in 1946, after graduation in 1945, he was my best man and I was his. Deemed unfit for military service because of a mild chronic facial lupus, Donald became an assistant medical officer …
CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects
Authors: R B Lydiard, J C Ballenger, M T Laraia, M D Fossey, M C Beinfeld
Journal: American Journal of Psychiatry (1992)

Cholecystokinin concentrations in the CSF of 25 patients with panic disorder and 16 normal comparison subjects were ascertained by radioimmunoassay. The patients with panic disorder had significantly lower CSF concentrations of cholecystokinin, which may reflect increased CNS cholecystokinin receptor sensitivity, reduced numbers of receptors, or a compensatory reduction in cholecystokinin octapeptide secondary to theoretically increased central cholecystokinin tetrapeptide activity.
OC-035 Association of oral and intravenous iron with the probability of hospitalisation in england
Authors: S Keshav, C Chapman, S Tomkins, L Mills, B Jackson
Journal: Gut (2015)

<h3>Introduction</h3> Iron deficiency anaemia (IDA) is the most common micronutrient deficiency worldwide, and is a major cause of referral to secondary care. Orally administered iron may inadequately control symptoms of IDA, particularly in those with underlying gastrointestinal (GI) conditions that impair iron absorption or cause bleeding. Inadequate treatment of IDA may increase the risk of hospital treatment and associated costs. In this study, the potential relationship of oral and intravenously administered iron with hospitalisation is examined in a retrospective cohort. <h3>Method</h3> Patients in England aged over 18 years with a GI condition and IDA between 1<sup>st</sup>Jan 2010–31<sup>st</sup>Oct 2013 were drawn from the HTI-CPRD dataset. Patients who attended hospital and received a prescription for IV or oral iron were included, and followed for hospitalisation within 30 days after the initial visit. The population is described in terms of demographic characteristics, comorbid conditions and common concomitant medications. Logistic regression was used to examine the association between hospitalisation within 30 days and the form of iron treatment. The duration of hospital stays was also examined. <h3>Results</h3> There were 4024 qualifying hospitalisations. Of 3143 patients receiving oral iron, 81% were hospitalised within 30 days. Of 881 patients receiving IV iron, 34% were hospitalised within 30 days. Hospital stays were longer in the oral iron group (min 0, max 120.2, median 5.4 days) compared with the IV group (0; 43.1; 1.2). The unadjusted odds ratio for a hospitalisation within 30 days for those prescribed IV compared to oral was 0.12, indicating substantially higher odds of hospitalisation in the oral group. The final model adjusted for confounders included age, gender, history of anaemia, elective and non-elective visit, menorrhagia, pregnancy, comcomitant treatment and history of reduced kidney function. The adjusted odds ratio (OR) was 0.49 (95% CI 0.41–0.59) demonstrating an attenuated but statistically significant reduced odds of hospitalisation in the IV iron group. <h3>Conclusion</h3> This study shows substantially reduced odds of hospitalisation amongst IDA patients when prescribed IV rather than oral iron. It is striking that the chance of hospitalisation after entry into the cohort was greater than even for those treated with oral iron, and less than even for those treated with IV iron. The magnitude of the apparent effect on morbidity suggests it is potentially clinically important and warrants further research. <h3>Disclosure of interest</h3> None Declared.
Evaluation of AC-601, a New Carbamate Anticonvulsant, in Therapy of Childhood Convulsive Disorders
Authors: E F DIAMOND
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MMPI profile of DSM-III borderline personality disorder
Authors: S Snyder, W M Pitts, W A Goodpaster, C Sajadi, Q Gustin
Journal: American Journal of Psychiatry (1982)

The authors compared the MMPI profile of 26 patients with DSM-III borderline personality disorder with than of 19 patients with dysthymic disorder. The clinical scales on which the borderline patients scored highest were psychasthenia and schizophrenia, but discriminant function analyses indicated that the L and F validity scales provided the model that best discriminated between the borderline and dysthymic groups.
Isolated lower extremity I-131 bone marrow uptake in a runner.
Authors: NICOLAAS BOHNEN, MARTIN CHARRON
Journal: Clinical Nuclear Medicine (2001)

From the Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Received for publication April 26, 2000. Accepted June 13, 2000. Reprint requests: Nicolaas I. Bohnen, M.D., Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh Medical Center, 3471 Fifth Avenue, Kaufman Building, Suite 811, Pittsburgh, Pennsylvania 15213.
Nodular prurigo—a clinical, biochemical and histological study
Authors: P.M. Hudson, M.M. Black, I.W. Whimster
Journal: British Journal of Dermatology (1978)

Journal Article Nodular prurigo—a clinical, biochemical and histological study Get access P.M. Hudson, P.M. Hudson Department of Dermatology, St Thomas' Hospital, London SE1 7EH Search for other works by this author on: Oxford Academic Google Scholar M.M. Black, M.M. Black Department of Dermatology, St Thomas' Hospital, London SE1 7EH Search for other works by this author on: Oxford Academic Google Scholar I.W. Whimster I.W. Whimster Department of Dermatology, St Thomas' Hospital, London SE1 7EH Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 99, Issue s16, 1 December 1978, Page 12, https://doi.org/10.1111/j.1365-2133.1978.tb15204.x Published: 01 December 1978
Studies on the Blood Supply of Tumors in Man. V. Skin Temperatures of Superficial Neoplastic Lesions
Authors: Howard R. Bierman, Rutherford S. Gilfillan, Keith H. Kelly, Oliver T. Kuzma, Morris Noble
Journal: JNCI Journal of the National Cancer Institute (1952)

Studies on the Blood Supply of Tumors in Man. V. Skin Temperatures of Superficial Neoplastic Lesions Get access Howard R. Bierman, Howard R. Bierman Laboratory of Experimental Oncology, National Cancer Institute, and the Division of Medicine, University of California School of Medicine3, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Rutherford S. Gilfillan, Rutherford S. Gilfillan Laboratory of Experimental Oncology, National Cancer Institute, and the Division of Medicine, University of California School of Medicine3, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Keith H. Kelly, Keith H. Kelly Laboratory of Experimental Oncology, National Cancer Institute, and the Division of Medicine, University of California School of Medicine3, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Oliver T. Kuzma, Oliver T. Kuzma Laboratory of Experimental Oncology, National Cancer Institute, and the Division of Medicine, University of California School of Medicine3, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Morris Noble Morris Noble Laboratory of Experimental Oncology, National Cancer Institute, and the Division of Medicine, University of California School of Medicine3, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 1, August 1952, Pages 1–17, https://doi.org/10.1093/jnci/13.1.1 Published: 01 August 1952 Article history Received: 21 January 1952 Published: 01 August 1952
SP0137 Low-Dose IL-2 Therapy in Refractory SLE: Early Insights from a Phase I/IIA Clinical Trial
Authors: J.Y. Humrich
Journal: Annals of the Rheumatic Diseases (2015)

Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies we have proven the significance of an acquired IL-2 deficiency and related Treg defects in the pathogenesis of systemic lupus erythematosus (SLE). Accordingly, we showed that compensation of IL-2 deficiency by IL-2 therapy corrects associated Treg defects and ameliorates already established disease in lupus-prone mice (1). Proceeding to a clinical translation, we recently reported a rapid and robust reduction of disease activity in parallel to a remarkable expansion of the Treg population by low-dose IL-2 therapy in one patient with refractory SLE (2). Together, these studies provided the rationales for the clinical implementation an IL-2-based immunotherapy for the treatment of SLE with the aim to restore Treg activity and thus to re-establish endogenous mechanisms of immune tolerance. Here, first promising results from the ongoing phase I/IIa clinical trial (PRO-IMMUN) addressing the safety, tolerability, immunological responses and clinical efficacy of a subcutaneous low-dose IL-2 therapy in patients with refractory SLE will be presented. <h3>References</h3> Humrich JY, et al. (2010) Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci USA 107(1):204-209. Humrich JY, et al. (2015) Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. doi: 10.1136/annrheumdis-2014-206506. <h3>Disclosure of Interest</h3> None declared
Cardiac Tuberculosis
Authors: Sanjay C. Dhar, Sean Hayes, Bojan Cercek, Michael C. Fishbein
Journal: Circulation (1998)

A 63-year-old man was admitted with a history suggestive of worsening heart failure over a duration of 6 months, recurrent ventricular tachyarrhythmias, poor response to medical treatment, and low-grade fever.a, Chest radiograph revealed right-sided pleural effusion, cardiomegaly, and borderline perihilar edema.b, CT scan of chest confirmed right-sided pleural effusion and also revealed pericardial effusion and pericardial thickening.c, Cross section of heart shows thickened pericardium.d, Close examination of apical myocardium (arrows) revealed myocardial tubercles.e, Higher magnification confirmed presence of granulomas (arrowhead) with giant cells and positive staining for acid-fast bacilli, not seen in this slide.
Bone Regeneration: Graphene Oxide‐Copper Nanocomposite‐Coated Porous CaP Scaffold for Vascularized Bone Regeneration via Activation of Hif‐1α (Adv. Healthcare Mater. 11/2016)
Authors: Wenjie Zhang, Qing Chang, Ling Xu, Guanglong Li, Guangzheng Yang, Xun Ding, Xiansong Wang, Daxiang Cui, Xinquan Jiang
Journal: Advanced Healthcare Materials (2016)

X. Wang, X. Jiang, and co-workers describe on page 1299, that the coating of CaP scaffolds with a novel graphene oxide-copper (GO-Cu) nano-composite can promote vascularized bone regeneration via upregulation of Hif-1α expression in stem cells. The GO-Cu nanocomposite coating provides an effective method for the in vivo application of graphene materials and copper ions in regenerative medicine.
AB1166 Socio-Economic and Professional Factors' Impact on Sleep Quality in Axial Spondyloarthritis Patients
Authors: R. Dhahri, I. Mahmoud, O. Saidane, I. Chrif, H. Sahli, R. Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Work and socio economic related factors have a great impact on patient9s quality of life. <h3>Objectives</h3> To explore the effect of work-related and socio-economic factors on quality of sleep in patients with Axial Spondyloarthritis (AS). To explore the effect of work-related and socio-economic factors on quality of sleep in patients with Axial Spondyloarthritis (AS). <h3>Methods</h3> A cross sectional case-control study was conducted between August 2012 and August 2013 in the department of Rheumatology of Charles Nicolle Hospital. Only patients with Axial Spondyloarthritis according to the 2009 Eular criteria were included. The 100 age- and sex-matched healthy controls were included in this case-control study. The patients and controls who had malignancy, fibromyalgia, serious infections or systemic diseases, and other chronic diseases were excluded from the study. Demographic characteristics, disease specific variables, years of education, marital status, disease duration, occupation and absenteeism during the three last months were documented for each patient. They answered a self-assessing: sleep quality the Medical outcome study sleep scale (MOS-SS). <h3>Results</h3> One hundred patients with AS and 100 control group patients age and sex matched participated in this study. Patients were divided into 71 men and 29 women. Their average age is 41.72 years [16-74].The majority of patients belonged to an average socioeconomic class (70%). 16% had a higher education, 68% secondary education, and 16% were illiterate. One-half of patients were unemployed and 26% displayed a disability related to their disease. Absenteeism was noted in 23% cases. The duration of the disease is on average 11.7 years and the age of disease onset is 28.9 years on average. In the group of women through, there were many more disruption sleep (p=0.016), headache/breathlessness on waking (p=0.008), and a fewer sleep hours amount (p=0.037). There was no difference between the sexes in terms of adequacy, sleepiness, snoring and sleep index I and II. Age was significantly correlated with sleepiness and areas snoring (p=0.002, p=0.001). The age of onset of the disease was significantly correlated with the areas drowsiness (p=0.015) and snoring (p=0.01) Comparison of sleep disorders by socio economic level showed that sleep adequacy, headache and breathlessness are more observed in disadvantaged class (p=0.022). Workplace absenteeism was related to sleep disorders in the area sleep disturbance with p=0.002. <h3>Conclusions</h3> Socio economic and professional status affects greatly the quality of life of patients and especially their sleep quality. <h3>Disclosure of Interest</h3> None declared
Comparison of the Reduction of Two Tetrazolium Salts with Succinoxidase Activity of Tissue Homogenates
Authors: Emma Shelton, Mary E. Rice
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Comparison of the Reduction of Two Tetrazolium Salts with Succinoxidase Activity of Tissue Homogenates Get access Emma Shelton, Emma Shelton National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary E. Rice Mary E. Rice National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 1, January 1957, Pages 117–125, https://doi.org/10.1093/jnci/18.1.117 Published: 01 January 1957 Article history Received: 24 September 1956 Published: 01 January 1957
AB1244-HPR Relationship Between Proprioception and Capsular Tightness in Patients with Adhesive Capsulitis
Authors: T. Zoroglu, S. Basar, R. Gunduz, S.H. Basaran, S.A. Kayis, Z. Hazar
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Adhesive capsulitis (AC) is characterized by a painful, gradual loss of both active and passive glenohumeral motion resulting from progressive fibrosis and ultimate contracture of the glenohumeral joint capsule. Fibrosis of the glenohumeral joint capsule can effect proprioception by stimulating mechanoreceptors. <h3>Objectives</h3> The aim of this study is to investigate the effect of capsular tightness on proprioception in patients with Adhesive Capsulitis. <h3>Methods</h3> Twenty five patients with adhesive capsulitis (21 female, 4 male; mean age 53±6 years; age range 44-67) were included in this study. Mean Body Mass Index (BMI) was 29.02±4.89. 11 dominant and 14 nondominant shoulder was measured. Proprioception was assessed with active repositioning process by inclinometer. Flexion, scapular elevation and rotations were assessed at mid range (MR) and end range (ER). Capsuler tightness (superior and mid fibers of posterior capsule, posterior capsule general, glenohumeral ligament (GHL)) was measured by a ruler and a universal goniometer. Relationship between proprioception and capsular tigtness was determined by Pearson correlation analysis. <h3>Results</h3> There was a significant, moderate and negative relationship between proprioception of external rotation at MR and ER and GHL (superior, middle and inferior GHL complex) tightness (p&lt;0.05). There was a significant, moderate and negative relationship between proprioception of external rotation at ER and general posterior capsule tightness (p&lt;0.05) ( Table 1). <h3>Conclusions</h3> In this study, our results showed that enhancement in tightness of capsule and GHL in patients with adhesive capsulitis increases proprioception of external rotation at MR and ER. This means that mechanoreceptors located within joint capsule are more sensitive at these ranges. Decreasing or eliminating tightness of capsule and GHL in patients with adhesive capsulitis may supply restructuring proprioception at normal range of motion. <h3>References</h3> Neviaser A.S., Hannafin J. A. Adhesive Capsulitis: A Review of Current Treatment. The American Journal of Sports Medicine, 2010; 38(11): 2346-56. Andrews J.R., Harrelson G. L., Wilk K.E.(Edited by). Physical Rehabilitation of the Injured Athlete.(Fourth edition). Philadelphia: Elsevier Saunders, 2012, 524-547. Yang JL, Jan MH, Hung CJ, Yang PL, Lin JJ. Reduced scapular muscle control and impaired shoulder joint position sense in subjects with chronic shoulder stiffness. J Electromyogr Kinesiol. 2010 Apr;20(2):206-11. <h3>Disclosure of Interest</h3> None declared